Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral beclomethasone dipropionate for gastrointestinal graft-versus-host disease
ACTRN12610000593033Phase 3Recruiting
- Sponsor
- Soligenix
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in graft-versus-host disease (GVHD) comparing Beclomethasone dipropionate + prednisone with Placebo + prednisone (2 arms). Primary endpoint: GVHD treatment failure proportion. Started Oct 2009; status: recruiting.
02
Drugs
beclomethasone dipropionate
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ACTRN12610000593033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000593033.